Circulating Biomarkers Associated With Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer
An exploratory biomarker analysis of the phase III TALAPRO-2 trial found that circulating tumor DNA (ctDNA) burden and reductions in circulating tumor cells (CTCs) were associated with radiographic progression–free survival in patients with metastatic castration-resistant prostate cancer receiving talazoparib plus enzalutamide or enzalutamide alone. The analysis, reported by Yip et al in The Lancet Oncology, also demonstrated strong agreement between ctDNA and tumor tissue testing for homologous recombination repair (HRR) gene alterations, supporting the potential complementary role of liquid biopsy in molecular profiling.
Study Details
TALAPRO-2 was a randomized, double-blind, placebo-controlled phase III trial evaluating first-line talazoparib plus enzalutamide vs placebo plus enzalutamide in patients with metastatic castration-resistant prostate cancer. Between January 2019 and September 2020, 805 patients unselected for HRR gene alterations were randomly assigned 1:1 to receive oral talazoparib at 0.5 mg plus enzalutamide at 160 mg daily (n = 402) or placebo plus enzalutamide (n = 403). Median follow-up for radiographic progression–free survival was 24.9 and 24.6 months, respectively.
The investigators compared HRR gene alteration status using prospectively tested tumor tissue and retrospectively analyzed baseline ctDNA samples. They also assessed the prognostic utility of baseline ctDNA burden, changes in ctDNA detectability at week 9, and CTC reductions at weeks 9 and 17. CTC conversion was defined as a reduction from at least five cells to four or fewer cells per 7.5 mL of blood; CTC0 was defined as a reduction from at least one cell to zero.
Key Results
Agreement in HRR gene alteration status between prospective tumor tissue testing and retrospective ctDNA testing was 84% (421 of 501 evaluable patients). Concordance was higher among patients with a ctDNA tumor fraction of at least 1% than among those with a fraction below 1% (89% vs 79%). Androgen receptor gene alterations were detected more frequently in ctDNA than in tumor tissue (33.8% vs 4.3%; P < .0001).
Detectable ctDNA at baseline was associated with significantly shorter radiographic progression–free survival in both treatment groups. Among patients receiving talazoparib plus enzalutamide, median radiographic progression–free survival was 21.0 months with detectable ctDNA vs not reached with undetectable ctDNA (hazard ratio [HR] = 2.46, 95% confidence interval [CI] = 1.68–3.60; P < .0001). Corresponding values in the placebo plus enzalutamide group were 11.0 vs 33.2 months (HR = 4.03, 95% CI = 2.85–5.72; P < .0001).
Conversion from detectable to undetectable ctDNA at week 9 was associated with improved outcomes compared with persistently detectable ctDNA. Median radiographic progression–free survival was 25.9 vs 10.8 months in the talazoparib group (HR = 1.66, 95% CI = 1.02–2.68; P = .037) and 16.5 vs 5.5 months in the placebo group (HR = 3.77, 95% CI = 2.39–5.94; P < .0001). Patients with persistently undetectable ctDNA had the most favorable outcomes.
CTC reductions were also associated with improved radiographic progression–free survival. At week 9, patients achieving CTC conversion had median radiographic progression–free survival of 22.1 vs 5.5 months without conversion in the talazoparib group (HR = 0.13, 95% CI = 0.06–0.32; P < .0001). Corresponding values in the placebo group were 16.6 vs 3.6 months (HR = 0.16, 95% CI = 0.07–0.40; P < .0001).
“Our results support broad prognostic utility of ctDNA burden and CTC enumeration in metastatic [castration–resistant] prostate cancer, including in the context of poly(ADP) ribose polymerase inhibitor therapy,” the authors concluded.
Steven M. Yip, MD , of the Arthur Child Comprehensive Cancer Centre and Cumming School of Medicine, University of Calgary, Calgary, AB T2N 5G2, Canada, is the corresponding author for the Lancet Oncology article.
DISCLOSURE : The study was supported by Pfizer. For full disclosures of the study authors, visit thelancet.com.